Bernhard J. Eigl
YOU?
Author Swipe
View article: Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer Open
This study provides the most comprehensive resource to date characterizing somatic alterations at the AR locus. Our clinicogenomic analysis establishes the repertoire and clinical relevance of AR genotypes in mCRPC, informing efforts to ta…
View article: Supplementary Table 3 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 3 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 3. Targeted cfDNA sequencing quality metrics.
View article: Supplementary Figure 1 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 1 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 1. Identification of ERBB2 mutations and copy number amplifications.
View article: Supplementary Figure 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 7. Allelic imbalance and clonality of oncogenic mutations detected in metastatic urothelial cancer (mUC) circulating tumor DNA (ctDNA).
View article: Supplementary Table 14 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 14 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 14. Agreement between ERBB2 genotype and HER2 IHC.
View article: Supplementary Table 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 6. Tissue tumor fraction estimation and ERBB2 alterations.
View article: Data from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Data from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Purpose:HER2 targeting is increasingly relevant in metastatic urothelial cancer (mUC) because of emerging antibody–drug conjugates, in which assessment of tumor HER2/ERBB2 status could aid interpretation of ongoing trials. We evalua…
View article: Supplementary Figure 9 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 9 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 9. Variance in HER2 IHC across urothelial cancer (UC) tumor tissue.
View article: Supplementary Figure 3 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 3 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 3. Breakage-fusion-bridge (BFB) events inferred from whole-genome sequencing of circulating tumor DNA.
View article: Supplementary Table 11 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 11 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 11. ERBB2 structural variants detected in whole-genome ctDNA sequencing.
View article: Supplementary Figure 4 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 4 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 4. Double minute (DM) inferred from whole-genome sequencing of circulating tumor DNA.
View article: Supplementary Table 13 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 13 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 13. Cohort of ERBB2-altered mUC based on ctDNA. List of all cfDNA samples with ERBB2 alterations.
View article: Supplementary Table 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 5. Genome-wide copy-number-based ctDNA fraction estimation. List of samples showing the copy number based tumor fraction estimation.
View article: Supplementary Table 10 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 10 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 10. Whole-genome cfDNA sequencing quality metrics.
View article: Supplementary Table 12 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 12 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 12. ERBB2 ecDNA detected in whole-genome ctDNA sequencing.
View article: Supplementary Table 4 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 4 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 4. Mutation-based ctDNA fraction estimation. List of samples showing the mutation used for tumor fraction estimation.
View article: Supplementary Figure 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 5. Genomic landscape from targeted circulating tumor DNA (ctDNA) sequencing of ERBB2-altered metastatic urothelial cancer (mUC).
View article: Supplementary Table 9 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 9 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 9. ERBB2 structural variants detected by targeted cfDNA sequencing.
View article: Supplementary Table 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 7. ERBB2 mutations detected in cfDNA.
View article: Supplementary Table 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 8. ERBB2 copy number in cfDNA.
View article: Supplementary Figure 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 6. Prognostic stratification of metastatic urothelial cancer (mUC) by ctDNA and tissue ERBB2/HER2 status and Eastern Cooperative Oncology Group (ECOG) performance status.
View article: Supplementary Figure 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 8. ERBB2 mutation dynamics across serial tissue and ctDNA samples.
View article: Supplementary Table 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 2. Tumor tissue cohort.
View article: Supplementary Figure 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 2. Targeted and whole-genome sequencing (WGS) of metastatic urothelial cancer (mUC) circulating tumor DNA (ctDNA).
View article: Supplementary Table 1 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 1 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 1. Cohort composition and mUC cfDNA samples.
View article: A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada
A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada Open
Introduction: Approximately 25% of patients diagnosed with bladder cancer have muscle-invasive disease (MIBC). While real-world data have highlighted opportunities to improve curative-intent treatment rates, comprehensive population-level …
View article: Machine Learning Model Integrating Computed Tomography Image–Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer
Machine Learning Model Integrating Computed Tomography Image–Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer Open
PURPOSE Chemotherapy is the primary treatment for metastatic nonseminomatous germ cell tumors (mNSGCTs), but patients often encounter postchemotherapy residual disease. Accurate noninvasive methods are needed to predict the histology of th…
View article: A population-based analysis of patterns of care in patients with high-risk non-muscle-invasive bladder cancer from Alberta, Canada
A population-based analysis of patterns of care in patients with high-risk non-muscle-invasive bladder cancer from Alberta, Canada Open
Introduction: Approximately three-quarters of patients newly diagnosed with bladder cancer have non-muscle-invasive disease (NMIBC). Among these patients, those with high-risk (HR) features should be managed more aggressively in an attempt…
View article: Fallbericht: Zwei Fälle von leptomeningealen Metastasen bei Patienten mit metastasiertem Urothelkarzinom, die mit Enfortumab Vedotin behandelt wurden
Fallbericht: Zwei Fälle von leptomeningealen Metastasen bei Patienten mit metastasiertem Urothelkarzinom, die mit Enfortumab Vedotin behandelt wurden Open
Hintergrund: Die leptomeningeale Karzinomatose ist ein außergewöhnlich seltenes Metastasenmuster bei Urogenitaltumoren, das in weniger als 0,1% der Fälle beschrieben wird. Wir berichten über 2 Fälle von Patienten mit metastasiertem Urothel…
View article: Author Correction: Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma
Author Correction: Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma Open